All Updates

All Updates

icon
Filter
Funding
Formation Bio raises USD 372 million in Series D funding to expand clinical portfolio and advance AI drug development
Clinical Trial Technology
Jun 26, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Clinical Trial Technology

Clinical Trial Technology

Jun 26, 2024

Formation Bio raises USD 372 million in Series D funding to expand clinical portfolio and advance AI drug development

Funding

  • AI-powered pharmaceutical company Formation Bio has raised USD 372 million in a Series D funding round led by Andreessen Horowitz (a16z), with participation from investors including Sanofi, Sequoia, Angel Growth, FPV Ventures, and more.

  • The proceeds will be allocated to the company’s strategies of acquiring and in-licensing clinical-stage assets from other biotech and pharma companies and enhancing its AI capabilities within drug development and clinical trials.

  • Formation Bio, formerly TrialSpark, accelerates drug development through a proprietary platform based on modern data, LLMs, AI agents, and other technology. The company acquires clinical-stage drugs from pharmaceutical companies, universities, and biotech firms and leverages its AI platform to develop these assets into commercialization.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.